Myriad Genetics (STU:MYD) Short Interest


STU:MYD Myriad Genetics Inc STU:MYD
53 GF Score
Price €5.01
GF Value €12.90
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:MYD vs PRE, FLGT, IMDX: Short Interest Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myriad Genetics Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Short Interest distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Short Interest falls into.


STU:MYD
53GF Score
Myriad Genetics Inc STU:MYD
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.01 is trading 61.1% below its estimated GF Value™ of €12.90. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • Short Interest:
  • GF Value™: €12.90 vs. price of €5.01 (61.1% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score

Get the complete analysis for STU:MYD

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.01
Price
€12.90
GF Value